PRMT5 loss in gastric cancer cells has also been shown to inhibit tumorigenesis in vitro and in xenograft models, which has been suggested to occur via epigenetic silencing of the tumor suppressor IRX1 although the role of H4R3me2s was unclear 23. This evidence concerns the gene PRMT5 and gastric cancer.